LPA and coronary artery disorder: Treatment with niacin or PCKS9 mAbs lowers Lp(a) modestly by 20–30% [60, 61] which is unlikely to provide significant clinical benefit as a Mendelian randomization analysis indicates that large absolute reductions in Lp(a) are likely required to meaningfully reduce the risk of coronary artery disease [62].